{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:24:56Z","timestamp":1787739896933,"version":"build-2784847793"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.autrev.2015.12.003","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T03:43:11Z","timestamp":1450323791000},"page":"281-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases"],"prefix":"10.1016","volume":"15","author":[{"given":"Patrick","family":"Cherin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Belizna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Cartry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgeta","family":"Lascu-Dubos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"de Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Delain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Crave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2015.12.003_bb0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0002-9343(91)90009-M","article-title":"Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients","volume":"91","author":"Cherin","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2015.12.003_bb0010","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.12.003_bb0015","first-page":"2230","article-title":"Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis","volume":"28","author":"Marie","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.12.003_bb0020","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.20325","article-title":"Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients","volume":"62","author":"Marie","year":"2010","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.autrev.2015.12.003_bb0025","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.12.003_bb0030","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0140-6736(90)91630-S","article-title":"Intravenous immunoglobulin for polymyositis and dermatomyositis","volume":"336","author":"Cherin","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2015.12.003_bb0035","first-page":"1092","article-title":"Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients","volume":"21","author":"Cherin","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.12.003_bb0040","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","article-title":"EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases","volume":"15","author":"Elovaara","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2015.12.003_bb0045","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrrheum.2010.2","article-title":"Immunotherapy of myositis: issues, concerns and future prospects","volume":"6","author":"Dalakas","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2015.12.003_bb0050","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.autrev.2010.03.003","article-title":"Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products","volume":"9","author":"Gurcan","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.12.003_bb0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1023\/A:1006678312925","article-title":"The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy","volume":"20","author":"Chapel","year":"2000","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2015.12.003_bb0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10875-006-9002-x","article-title":"Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies\u2014a prospective, multi-national study","volume":"26","author":"Gardulf","year":"2006","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2015.12.003_bb0065","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.iac.2008.07.002","article-title":"Subcutaneous administration of IgG","volume":"28","author":"Berger","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.autrev.2015.12.003_bb0070","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","article-title":"Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application","volume":"10","author":"Danieli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.12.003_bb0075","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000441490","article-title":"Subcutaneous immunoglobulin use in inclusion body myositis: a review of 6 cases","volume":"7","author":"Cherin","year":"2015","journal-title":"Case Rep Neurol"},{"key":"10.1016\/j.autrev.2015.12.003_bb0080","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mus.23895","article-title":"Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia","volume":"48","author":"Pars","year":"2013","journal-title":"Muscle Nerve"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2015.12.003_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2249.2009.04027.x","article-title":"Subcutaneous immunoglobulin: opportunities and outlook","volume":"158","author":"Misbah","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2015.12.003_bb0090","article-title":"Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence","author":"Cherin","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.12.003_bb0095","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10067-013-2478-x","article-title":"Open-label study on treatment with 20% subcutaneous IgG administration in polymyositis and dermatomyositis","volume":"33","author":"Danieli","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2015.12.003_bb0100","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.12.003_bb0105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2015.12.003_bb0110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2249.2009.04028.x","article-title":"6th International immunoglobulin symposium: poster presentations","volume":"158","author":"Fernandez-Cruz","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2015.12.003_bb0115","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1529-8027.2011.00330.x","article-title":"A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study","volume":"16","author":"Misbah","year":"2011","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.autrev.2015.12.003_bb0120","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/WNL.58.2.326","article-title":"Intravenous immunoglobulin for dysphagia of inclusion body myositis","volume":"58","author":"Cherin","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2015.12.003_bb0125","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10875-007-9169-9","article-title":"Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration","volume":"28","author":"Quinti","year":"2008","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2015.12.003_bb0130","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.autrev.2014.08.018","article-title":"Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review","volume":"13","author":"Danieli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.12.003_bb0135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1529-8027.2009.00218.x","article-title":"Subcutaneous immunoglobulin therapy for multifocal motor neuropathy","volume":"14","author":"Eftimov","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.autrev.2015.12.003_bb0140","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/ene.12080","article-title":"Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"20","author":"Markvardsen","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2015.12.003_bb0145","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2015.12.003_bb0150","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s10875-006-9031-5","article-title":"Patients' attitude to subcutaneous immunoglobulin substitution as home therapy","volume":"26","author":"Kittner","year":"2006","journal-title":"J Clin Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215002608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215002608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T19:22:47Z","timestamp":1537125767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997215002608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1568997215002608"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2015.12.003","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2015.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}